 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
|
Neutropenia
|
|
Neulasta® on First Day of Chemotherapy May Be More Convenient for Gynecologic Cancers (3/18/2008)
Researchers from the University of Alabama have reported that the administration of Neulasta® (pegfilgrastim) on the first day of chemotherapy among women with gynecologic cancers may be as effective as and more convenient than second-day administration. These results were recently reported at the 2008 annual Society of Gynecologic Oncologists meeting.
Neulasta® Facilitates Chemotherapy Administration and Reduces Febrile Neutropenic Hospitalizations (9/28/2007)
Researchers involved in an international randomized trial have reported that the prophylactic administration of Neulasta (pegfilgrastim) is associated with improved chemotherapy delivery, reduces febrile neutropenia (FN) and decreases hospitalization compared to current practice of neutropenia management. The details of this study were presented at the European CanCer Organization (ECCO) 14th European Cancer Conference meeting in Barcelona, Spain.
Prophylactic Colony-Stimulating Factors have No Effect on Mortality but Decrease Infections (9/25/2007)
Researchers from Canada have reported that the use of prophylactic hematopoietic colony-stimulating factors (CSFs) decrease febrile neutropenia and infection but have no impact on survival. The details of this meta-analysis were reported in the September 18, 2007 issue of the Annals of Internal Medicine.
Neulasta® Decreases Neutropenia in Patients with Colorectal Cancer Receiving Every 2 Week Chemotherapy (8/8/2007)
Researchers involved in a multi-center US randomized Phase II trial have reported that Neulasta® (pegfilgrastim) was effective in preventing grade 3-4 neutropenia in patients with locally advanced or metastatic colorectal cancer receiving one of three chemotherapy regimens. The details of this study were presented at the 9th World Congress on Gastrointestinal Cancer in Barcelona, June 28- July 1.
Prophylactic G-CSF Reduces Febrile Neutropenia and Early Infectious Deaths (7/24/2007)
Researchers from the University of Rochester, the University of Washington and Duke University have concluded that the prophylactic use of granulocyte-colony stimulating factor (G-CSF) reduces febrile neutropenia and early deaths due to infections in adult patients receiving chemotherapy. The details of this study appeared in the July 10, 2007 issue of the Journal of Clinical Oncology.
ASCO Guidelines for Use of White Blood Cell Growth Factors Published (7/19/2006)
The American Society of Clinical Oncology (ASCO) has published the 2006 update of recommendations for the use of white blood cell growth factors such as Neupogen® (filgrastim) or Neulasta® (pegfilgrastim) for prevention of neutropenia. These updated recommendations were published in the July 1, 2006, issue of the Journal of Clinical Oncology.
Low Incidence of Neutropenic Complications Among Patients Treated with Neulasta® in Community Setting (6/6/2006)
According to the final results of a large prospective study presented at the 2006 annual meeting of the American Society of Clinical Oncology, providing Neulasta® (pegfilgrastim) to patients undergoing myelosuppressive chemotherapy results in a low occurrence of neutropenic complications and a low occurrence of chemotherapy dose or schedule alterations related to neutropenia.
Neulasta® and Aranesp® Provide Effective Hematopoietic Support for Dose-Dense Chemotherapy (11/21/2005)
Researchers from the Dana Farber Cancer Centerhave reported that the prophylactic administration of pegfilgrastim (Neulasta) and darbepoetin alfa (Aranesp) was effective and safe for prevention of febrile neutropenia and anemia in women receiving adjuvant dose-dense chemotherapy for the adjuvant treatment of localized breast cancer.
Prophylactic G-CSFs May Reduce Infection-Related Mortality (11/11/2005)
Researchers from the University of Rochester have reported that the use of prophylactic granulocyte-colony stimulating factor (G-CSF) may reduce the risk of infection-related mortality in cancer patients.
Neupogen® Plus Antibiotics Decrease Febrile Neutropenia in Small Cell Lung Cancer (11/8/2005)
Researchers from the Netherlands have reported that the addition of Neupogen (granulocyte-colony stimulating factor) to prophylactic antibiotics decreases febrile neutropenia in patients with small cell lung cancer (SCLC) undergoing intensive sequential chemotherapy.
Levaquin® Prevents Bacterial Infection in Neutropenic Cancer Patients (9/9/2005)
Two randomized studies were published in the September 8, 2005, issue of the New England Journal of Medicine suggesting benefit from prophylactic Levaquin (levofloxacin) administration in patients with chemotherapy-induced neutropenia.
Neutropenia During Chemotherapy Associated with Improved Survival of NSCLC (8/10/2005)
Researchers from Italy have reported that patients with advanced non-small cell lung cancer (NSCLC) who receive chemotherapy have a better survival if they develop neutropenia compared to patients who do not develop neutropenia. These authors suggest that neutropenia is a surrogate marker for optimal dosing of chemotherapy.
Risk of Neutropenia Highest During the First Cycle of Chemotherapy (7/28/2005)
Researchers from the United States have reported that an initial episode of severe neutropenia or febrile neutropenia is most likely to occur during the first cycle of chemotherapy.
Updated Meta-Analysis Shows Prophylactic G-CSFs Significantly Reduces the Risk of Infection-Related Mortality (7/7/2005)
Researchers from the United States have reported that prophylactic recombinant human granulocyte colony-stimulating factors (G-CSFs) not only reduce the risk of febrile neutropenia across a wide variety of malignancies, chemotherapy regimens, and risk factors, but also significantly reduce the risk of infection-related mortality.[1]
Significant Decline in Patient-Reported Quality of Life with the Onset of Severe Neutropenia (7/7/2005)
Researchers from the United States have reported results of a clinical trial that indicate patients who experience grade 3-4 neutropenia report greater symptom distress than those with grade 2-3 and experience significant impairment in quality of life.
Hospitalization of Neutropenic Patients Has High Costs (5/3/2005)
Researchers from the Sutter Cancer Center in Sacramento have reported that hospitalization for complications of neutropenia affect over 60,000 U.S. patients per year with a mortality rate of 6.8% and a cost per hospitalization of $13,372.
Neulasta® Prevents Febrile Neutropenia in Breast Cancer Patients (2/24/2005)
A multi-center international trial has determined that first and subsequent cycle use of Neulasta® (pegfilgrastim) with a moderately myelosuppressive chemotherapy regimen significantly reduced febrile neutropenia, febrile neutropenia-related hospitalizations, and IV anti-infective use. The details of this report appeared in the February 20, 2005 issue of the Journal of Clinical Oncology. This data was also presented at the 2004 San Antonio Breast Cancer Symposium.
A Single Dose of Neulasta® is as Effective as 16 Doses of Neupogen® in Remission Induction of AML (12/28/2004)
According to results recently presented at the 46th annual meeting of the American Society of Hematology (ASH), Neulasta® (pegfilgrastim) appears at least as effective as Neupogen® (filgrastim) in the treatment of chemotherapy-induced neutropenia in patients with acute myeloid leukemia (AML). One injection of Neulasta® was comparable to 16 injections of Neupogen® in this group of patients.
Meta-Analysis Suggests that Prophylactic Colony-Stimulating Factors Decrease Febrile Neutropenia in Children with Cancer (8/25/2004)
Researchers from the U.S. and Canada performed a meta-analysis of 16 randomized controlled trials of colony stimulating factors (CSFs) in children with cancer. They concluded from these analyses that CSFs reduced the rate of febrile neutropenia by 20%, reduced documented infections by 22%, reduced amphotericin B use by 50%, and decreased hospitalization duration by approximately 2 days, but had no effect on infection-related mortality. The details of this study were reported in the August 15, 2004 issue of the Journal of Clinical Oncology.
Single Dose Neulasta® Effective for Mobilization of Peripheral Blood Stem Cells (4/7/2004)
Researchers from Dresden have reported that a single 6 mg injection of Neulasta® (pegfilgrastim) was as effective as multiple days of granulocyte-colony stimulating factor filgrastim (Neupogen®) for the mobilization of peripheral blood stem cells in patients undergoing autologous transplantation. The results of this study were presented at the 30th annual meeting of the European Group for Bone Marrow Transplantation in Barcelona on March 2004.
A Single Dose of Neulasta" is Equivalent to 11 Daily Injections of Neupogen® (3/4/2003)
Pegylation is a technique that allows for the slow delivery of biologic agents, cutting down the need for daily dosing. It has been used successfully to develop
Aranesp®, which is a long-acting form of recombinant human erythropoietin. Aranesp® can be given at weekly or longer intervals. The same technology has been used to develop
Neulasta® (pegfilgrasim), a long-acting form of recombinant granulocyte colony stimulating factor (G-CSF, Neupogen®). A multi-center randomized trial compared daily
Neupogen® to once per cycle injection of Neulasta™ in patients with non-Hodgkin’s Lymphoma (NHL) undergoing chemotherapy.
1
The results of this trial were published in the February 1, 2002 issue of the
Journal of Clinical Oncology.
Prophylactic Antibiotics Prevent Neutropenic Fever but Drug Resistance May be Emerging (2/28/2003)
For over 10 years, antibiotics have been routinely administered to prevent infections during periods of neutropenia following the administration of chemotherapy. The most commonly used antibiotic is ciprofloxacin either alone or in combination. The choice of this antibiotic over the past decade is due to good oral absorption and a broad spectrum of activity. There have, however, been many recent reports of drug resistance and few studies have documented the cost-effectiveness of this approach. In the February 2003 issue of the
Annals of Oncology, researchers affiliated with the European Organization for the Treatment and Research of Cancer (EORTC) reported on the combination of ciprofloxacin and roxithromycin, which is an antibiotic related to erythromycin.
1
Roxithromycin is used to prevent gram- positive infections, is active against crypotosporidiosis and is used frequently in Europe for patients with HIV infection.
Increased Doses of Aranesp® for Four Weeks Hasten Recovery From Chemotherapy-Induced Anemia (2/27/2003)
Aranesp® is a long-acting form of erythropoietin (rHuEPO) which was approved in July of 2002 by the U.S. Food and Drug Administration for the treatment of anemia in patients with cancer receiving chemotherapy. The usual schedule for erythropoietin is one to three times per week, whereas Aranesp® can be given on a weekly schedule. However, optimal dose and schedule of Aranesp® is still under investigation. Aranesp® is usually given at a dose of 4.5 µg/kg per week. Researchers from UCLA School of Medicine, Hematology-Oncology Associates of Jacksonville, Pacific Coast Hematology Oncology Medical Group and Amgen Inc. have reported that the administration of high loading doses of Aranesp® may hasten recovery from chemotherapy-induced anemia. They published the results of their trial in the March issue of
Cancer.
Long-Acting Single Dose Pegylated Filgrastim Found Effective in Randomized Trial (12/26/2002)
Pegylation is a technique that allows for the slow delivery of biologic agents, cutting down the need for daily dosing. It has been used successfully to develop Aranesp® which is a long-acting form of recombinant human erythropoietin. Aranesp® can be given at weekly or longer intervals. The same technology has been used to develop a long-acting form of recombinant granulocyte colony stimulating factor (G-CSF). Researchers in Germany performed a randomized controlled trial to compare pegylated filgrastim (pegfilgrastim,
Neulasta™) to
Neupogen®. They reported their results of this trial in the January 2003 issue of the
Annals of Oncology.
Ethyol® May Prevent Granulocytopenia in Children Being Treated for Osteosarcoma (5/22/2002)
According to results recently published in the
Journal of Pediatric Hematology-Oncology, Ethyol® (amifostine) decreases the incidence of granulocytopenia in patients undergoing treatment for osteogenic sarcoma.
Component of Red Wine Has Potential Anti-cancer Properties (5/20/2002)
According to results recently published in the
British Journal of Cancer, the cancer preventive agent resveratrol metabolizes into the anti-leukemic agent piceatannol, which may provide a novel explanation for the cancer preventive properties of resveratrol.
|
|
Patient Home
